Lebrikizumab plus TCS shows sustained disease control in refractory atopic dermatitis – Hospital Healthcare Europe
Share
Lebrikizumab plus TCS shows sustained disease control in refractory atopic dermatitis Hospital Healthcare Europe
Source link

